The Skinny Shot

What do the clinical trial documents actually show? What did the FDA reviewers flag before approval? And what happened in the years after semaglutide and tirzepatide flooded the market?

The Skinny Shot is a citizen's investigation into the GLP-1 approval record, drawing on FDA briefing documents, published trial protocols, post-marketing safety reports, and public court records. This book does not tell you what to take. It tells you what the data says.

Inside, you will find a close reading of the original clinical trials: what they measured, what they excluded, and what the long-term follow-up data looks like. You will see how the regulatory process unfolded under pressure from both patients and pharmaceutical companies, and what the post-approval safety signals have shown since these drugs reached tens of millions of people.

Topics covered include: the mechanism behind GLP-1 receptor agonists, the SURMOUNT and SUSTAIN trial results, FDA advisory committee transcripts, reported adverse events including thyroid concerns and gastrointestinal complications, the rebound weight data, and the open questions that no manufacturer has fully answered.

This is not a diet book. It is an investigation for anyone who wants to understand the evidence before forming an opinion.